skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction

Original Research

(1380) Views  (521) Full article downloads

Authors: Paul T Wilder, Thomas H Charpentier, Melissa A Liriano, et al

Published Date July 2010 Volume 2010:1 Pages 109 - 126
DOI: http://dx.doi.org/10.2147/IJHTS.S8210

Paul T Wilder1,2, Thomas H Charpentier1, Melissa A Liriano1, Kira Gianni1, Kristen M Varney1, Edwin Pozharski3, Andrew Coop3, Eric A Toth1, Alex D MacKerell3, David J Weber1,2

1Department of Biochemistry and Molecular Biology, The University of Maryland School of Medicine, 2HTS Center, University of Maryland Greenebaum Cancer Center, 3Department of Pharmaceutical Sciences, The University of Maryland School of Pharmacy, MD, USA

Abstract: S100B is highly over-expressed in many cancers, including malignant melanoma. In such cancers, S100B binds wild-type p53 in a calcium-dependent manner, sequestering it, and promoting its degradation, resulting in the loss of p53-dependent tumor suppression activities. Therefore, S100B inhibitors may be able to restore wild-type p53 levels in certain cancers and provide a useful therapeutic strategy. In this regard, an automated and sensitive fluorescence polarization competition assay (FPCA) was developed and optimized to screen rapidly for lead compounds that bind Ca2+-loaded S100B and inhibit S100B target complex formation. A screen of 2000 compounds led to the identification of 26 putative S100B low molecular weight inhibitors. The binding of these small molecules to S100B was confirmed by nuclear magnetic resonance spectroscopy, and additional structural information was provided by X-ray crystal structures of several compounds in complexes with S100B. Notably, many of the identified inhibitors function by chemically modifying Cys84 in protein. These results validate the use of high-throughput FPCA to facilitate the identification of compounds that inhibit S100B. These lead compounds will be the subject of future optimization studies with the ultimate goal of developing a drug with therapeutic activity for the treatment of malignant melanoma and/or other cancers with elevated S100B.

Keywords: nuclear magnetic resonance, fluorescence polarization, melanoma, chlorpromazine, thimerosal, sanguinarine






Readers of this article also read:

Alogliptin: a new addition to the class of DPP-4 inhibitors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Everolimus-eluting stents: update on current clinical studies
Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio